Navigation Links
Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008
Date:5/7/2008

MONTVALE, N.J., May 7 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced today that it will report its first quarter 2008 financial results on Wednesday, May 14, 2008, before the U.S. financial markets open. Management will provide a Company update and discuss the first quarter results during a conference call the same day, at 9:00 a.m. EST.

Investors and other interested parties may access the call as follows:

Date: Wednesday, May 14, 2008

Time: 9:00 a.m. EDT

Telephone (U.S.): 866.356.4441

Telephone (international): 617.597.5396

Participant Passcode: 80809977

Webcast: http://www.memorypharma.com under the

"Investors" section

An audio replay of the conference call will be available from 11:00 a.m. EDT on Wednesday, May 14, 2008, until Wednesday, May 21, 2008. To access the replay, please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enter pass code number 14991737. An audio replay of the conference call will also be available under the "Investors" section of the Company's website during the same period.

About Memory Pharmaceuticals

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at http://www.memorypharma.com.


'/>"/>
SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Memory in artificial atoms
2. Memory Pharmaceuticals Receives Nasdaq Notification
3. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
4. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
5. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
6. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
8. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
9. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
10. ASU researchers improve memory devices using nanotech
11. BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... According to a report by Transparency Market Research (TMR), ... the presence of a large pool of participants; however, only a ... Sigma-Aldrich, compete with each other in this market. With Proliant being ... of this market in 2016.  ... As of now, a large number of vendors are ...
(Date:3/22/2017)... 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today ... (RGC), U.K. Biobank and GSK to generate genetic sequence data ... The initiative will enable researchers to gain valuable insights to ... wide range of serious and life threatening diseases. ... Genetic evidence ...
(Date:3/22/2017)... -- Good Start Genetics, a leading family genomics company, ... covered lives mark through its most recent payor addition, ... . With newly signed contracts nationally and others in ... acceptance based on the quality of its science, the ... industry-leading customer care and support and its published cost-effectiveness ...
Breaking Biology Technology:
(Date:3/1/2017)... March 1, 2017  Aware, Inc. (NASDAQ: AWRE), a ... Richard P. Moberg has resigned, effective March ... Chief Financial Officer and Treasurer of Aware citing a ... as a member of the Board of Directors of ... co-Chief Executive Officer and co-President, General Counsel has been ...
(Date:2/26/2017)...  Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, announces the appointment of ... "Too often, too many offenders return to jail ... trying to tackle this ongoing problem and improve ... members. While significant steps are underway, Securus continues to ...
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
Breaking Biology News(10 mins):